Document is current
Any future updates will be listed below
-
Authors
Bonanni, Paolo https://orcid.org/0000-0003-2875-3744
Heo, Jung Yeon https://orcid.org/0000-0002-6548-1939
Honda, Hitoshi https://orcid.org/0000-0002-4870-0730
Lee, Ping-Ing https://orcid.org/0000-0002-7299-2825
Mouliom, Aminatou https://orcid.org/0000-0001-9404-7325
Leong, Hoe Nam
del Pilar Martin Matos, Maria
Dawson, Rachel
-
Funding
Funding for this research was provided by:
Moderna
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 11 March 2025
First Online: 10 April 2025
Declarations
:
: Paolo Bonanni received grants for epidemiological and health technology assessment (HTA) research from different vaccine companies (GSK, MSD, Sanofi Pasteur, Pfizer, Seqirus, AstraZeneca) and fees for taking part in advisory boards on different vaccines from the same companies and from Moderna, Inc., and Janssen. Hitoshi Honda received honoraria from Shionogi, Moderna, Inc., bioMérieux, Takeda, and Pfizer; and received consulting fees from Solventum. Jung Yeon Heo has no potential conflicts of interest to declare. Hoe Nam Leong has received consulting fees from GSK and honoraria for talks from Sanofi Pasteur. Maria del Pilar Martin Matos is an employee of Moderna, Inc., and may hold stock/stock options in the company. Rachel Dawson was an employee of Moderna, Inc., at the time of manuscript writing and is a current employee of Sanofi. Aminatou Mouliom was an employee of Moderna, Inc., at the time of manuscript writing and has no other potential conflicts of interest to declare. Ping-Ing Lee has no commercial or financial relationships to declare that could be construed as a potential conflict of interest.
: Ethical approval was not sought or obtained as this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
